Takeda Pharmaceutical Company Limited Share Price Deutsche Boerse AG
Stocks
TKD
JP3463000004
Pharmaceuticals
OTC Markets Traded|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.12 EUR | +0.85% |
|
+3.50% | +15.27% |
| 08-06 | Takeda Wins FDA Approval for First-in-Class Narcolepsy Treatment ORZEYFUL | MT |
| 08-06 | Takeda Receives U.S. Fda Approval for Orzeyful (Oveporexton) to Treat Narcolepsy Type 1 | CI |
| Market Cap | 8,913B 56.09B 48.56B 45.39B 41.48B 78.17B 5,349B 79.39B 532B 209B 2,676B 211B 206B | P/E 2027 * |
44.5x | P/E 2028 * | 27.7x |
|---|---|---|---|---|---|
| Enterprise Value | 12,837B 80.78B 69.93B 65.37B 59.74B 113B 7,704B 114B 767B 301B 3,854B 303B 297B | EV / Sales 2027 * |
2.75x | EV / Sales 2028 * | 2.66x |
| Free-Float |
99.28% | Yield 2027 * |
3.66% | Yield 2028 * | 3.73% |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 day | +0.85% | ||
| 1 week | +3.50% | ||
| Current month | +0.91% | ||
| 1 month | +4.07% | ||
| 3 months | +7.36% | ||
| 6 months | -1.35% | ||
| Current year | +15.27% |
| 1 week | 28.69 |  | 30.27 |
| 1 month | 28.16 | | 31.24 |
| Current year | 25.46 | | 32.02 |
| 1 year | 22.45 | | 32.02 |
| 3 years | 22.45 | | 32.02 |
| 5 years | 22.45 | | 32.02 |
| 10 years | 22.45 | | 50 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 31/12/2024 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 31/03/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 47 | 31/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 60 | 31/05/2015 |
Steven Gillis
BRD | Director/Board Member | 73 | 31/12/2018 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 31/05/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.85% | +3.50% | - | - | 56.09B | |
| +3.90% | +9.86% | +96.91% | +136.30% | 1,098B | |
| +0.99% | +2.91% | +51.05% | +52.06% | 631B | |
| +0.78% | +1.17% | +25.21% | +63.74% | 438B | |
| -0.08% | +4.14% | +51.24% | +40.49% | 368B | |
| +0.06% | +1.78% | +32.08% | +39.70% | 298B | |
| -0.53% | +1.44% | +7.91% | +7.97% | 251B | |
| +1.52% | +10.12% | +44.75% | +59.20% | 226B | |
| +0.86% | +0.28% | -4.39% | -50.30% | 209B | |
| -0.11% | +1.46% | +11.43% | +66.32% | 165B | |
| Average | +0.17% | +1,657.21% | +35.13% | +46.17% | 409.37B | |
| Weighted average by Cap. | -0.00% | +1,331.50% | +51.88% | +68.66% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,671B 29.39B 25.45B 23.78B 21.74B 40.96B 2,803B 41.6B 279B 109B 1,402B 110B 108B | 4,749B 29.89B 25.87B 24.18B 22.1B 41.65B 2,850B 42.3B 284B 111B 1,426B 112B 110B |
| Net income | 192B 1.21B 1.05B 978M 894M 1.68B 115B 1.71B 11.47B 4.5B 57.68B 4.54B 4.44B | 318B 2B 1.73B 1.62B 1.48B 2.79B 191B 2.83B 18.97B 7.44B 95.36B 7.5B 7.34B |
| Net Debt | 3,924B 24.69B 21.38B 19.98B 18.26B 34.41B 2,355B 34.95B 234B 91.94B 1,178B 92.72B 90.69B | 3,715B 23.38B 20.24B 18.92B 17.29B 32.58B 2,230B 33.09B 222B 87.05B 1,116B 87.79B 85.88B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/08/26 | €29.90 | +0.10% | 0 |
| 10/08/26 | €29.87 | -0.50% | 28 |
| 07/08/26 | €30.02 | +1.52% | 0 |
| 06/08/26 | €29.57 | +1.55% | 100 |
| 05/08/26 | €29.12 | +0.80% | 174 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
- TKD Stock
Select your edition
All financial news and data tailored to specific country editions
